Company Quick10K Filing
Quick10K
Livongo Health
10-Q 2019-06-30 Quarter: 2019-06-30
S-1 2019-06-28 Public Filing
8-K 2019-10-07 Regulation FD, Exhibits
8-K 2019-09-05 Earnings, Regulation FD, Exhibits
DVMT Dell 67,852
KAAC Kayne Anderson Acquisition 3,188
MEC Mayville Engineering 260
INIS International Isotopes 34
LEXE Liberty Expedia Holdings 0
WSCI WSI Industries 0
GNTH Genethera 0
DOYU DouYu 0
MDFZF Medifocus 0
ENTB Entest Group 0
LVGO 2019-06-30
Part I - Financial Information
Item 1. Financial Statements.
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Qualitative and Quantitative Disclosures About Market Risk
Item 4. Controls and Procedures
Part II - Other Information
Item 1. Legal Proceedings
Item 1A. Risk Factors
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 3. Defaults Upon Senior Securities
Item 4. Mine Safety Disclosures
Item 5. Other Information
Item 6. Exhibits
EX-3.1 lvgo-20190630x10qxex31.htm
EX-3.2 lvgo-20190630x10qxex32.htm
EX-31.1 lvgo-20190630x10qxex311.htm
EX-31.2 lvgo-20190630x10qxex312.htm
EX-32.1 lvgo-20190630x10qxex321.htm
EX-32.2 lvgo-20190630x10qxex322.htm

Livongo Health Earnings 2019-06-30

LVGO 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

Document
false--12-31Q2201900016392257850006300069400028000250000250000575000105400030000030000030000080000011000000.802.2800.36078500063000694000280000.0010.001992500001000000001769100020890000176910002089000010000010000010000000000P6M1DP4Y01.520.02080.50.52376500002376500000.0010.00158615000600000005861500058615000 0001639225 2019-01-01 2019-06-30 0001639225 2019-08-31 0001639225 2019-06-30 0001639225 2018-12-31 0001639225 2018-01-01 2018-06-30 0001639225 2018-04-01 2018-06-30 0001639225 2019-04-01 2019-06-30 0001639225 us-gaap:CommonStockMember 2018-12-31 0001639225 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001639225 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001639225 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001639225 us-gaap:CommonStockMember 2017-12-31 0001639225 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001639225 2018-06-30 0001639225 us-gaap:RetainedEarningsMember 2017-12-31 0001639225 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001639225 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0001639225 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0001639225 us-gaap:RetainedEarningsMember 2018-06-30 0001639225 2017-12-31 0001639225 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001639225 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001639225 us-gaap:RetainedEarningsMember 2019-06-30 0001639225 us-gaap:CommonStockMember 2019-06-30 0001639225 us-gaap:CommonStockMember 2018-06-30 0001639225 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001639225 us-gaap:RetainedEarningsMember 2018-12-31 0001639225 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001639225 2018-03-31 0001639225 us-gaap:CommonStockMember 2018-03-31 0001639225 2019-03-31 0001639225 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001639225 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001639225 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001639225 us-gaap:CommonStockMember 2019-03-31 0001639225 us-gaap:RetainedEarningsMember 2019-03-31 0001639225 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001639225 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001639225 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001639225 us-gaap:RetainedEarningsMember 2018-03-31 0001639225 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001639225 lvgo:MyStrengthMember 2019-01-01 2019-06-30 0001639225 lvgo:RetrofitMember 2019-01-01 2019-06-30 0001639225 us-gaap:RedeemableConvertiblePreferredStockMember 2019-01-01 2019-06-30 0001639225 us-gaap:RedeemableConvertiblePreferredStockMember 2018-01-01 2018-06-30 0001639225 lvgo:MyStrengthMember 2018-01-01 2018-06-30 0001639225 lvgo:RetrofitMember 2018-01-01 2018-06-30 0001639225 us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2019-07-01 2019-07-31 0001639225 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2019-07-01 2019-07-31 0001639225 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2019-07-01 2019-07-31 0001639225 us-gaap:SubsequentEventMember us-gaap:IPOMember 2019-07-01 2019-07-31 0001639225 us-gaap:SubsequentEventMember us-gaap:IPOMember 2019-07-31 0001639225 us-gaap:SubsequentEventMember 2019-07-31 0001639225 us-gaap:AdditionalPaidInCapitalMember us-gaap:SubsequentEventMember 2019-07-01 2019-07-31 0001639225 us-gaap:CommonStockMember 2019-06-27 2019-06-27 0001639225 us-gaap:RedeemableConvertiblePreferredStockMember 2019-06-27 2019-06-27 0001639225 lvgo:PartnerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-06-30 2019-06-30 0001639225 lvgo:PartnerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-04-01 2019-06-30 0001639225 lvgo:PartnerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-04-01 2018-06-30 0001639225 lvgo:PartnerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-06-30 0001639225 lvgo:PartnerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-04-01 2019-06-30 0001639225 lvgo:PartnerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-12-31 2018-12-31 0001639225 lvgo:PartnerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-06-30 2019-06-30 0001639225 lvgo:PartnerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-06-30 0001639225 lvgo:PartnerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-06-30 0001639225 lvgo:PartnerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-12-31 2018-12-31 0001639225 lvgo:RetrofitMember 2018-04-30 0001639225 lvgo:MyStrengthMember 2019-01-01 2019-06-30 0001639225 lvgo:MyStrengthMember 2019-02-01 2019-02-28 0001639225 lvgo:MyStrengthMember 2019-04-01 2019-06-30 0001639225 lvgo:RetrofitMember 2019-06-30 0001639225 lvgo:RetrofitMember 2019-04-01 2019-06-30 0001639225 lvgo:RetrofitMember 2018-04-01 2018-04-30 0001639225 lvgo:MyStrengthMember 2019-02-28 0001639225 lvgo:RetrofitMember 2018-04-01 2018-06-30 0001639225 lvgo:RetrofitMember 2018-12-31 0001639225 lvgo:RetrofitMember 2019-04-01 2019-04-30 0001639225 lvgo:MyStrengthMember 2019-06-30 0001639225 lvgo:RetrofitMember 2019-01-01 2019-06-30 0001639225 lvgo:FormerRetrofitStockholdersMember lvgo:RetrofitMember 2019-04-01 2019-04-30 0001639225 lvgo:RetrofitMember 2018-01-01 2018-12-31 0001639225 lvgo:RetrofitMember 2018-01-01 2018-06-30 0001639225 lvgo:RetrofitMember us-gaap:DevelopedTechnologyRightsMember 2018-04-01 2018-04-30 0001639225 lvgo:RetrofitMember us-gaap:TradeNamesMember 2018-04-01 2018-04-30 0001639225 lvgo:RetrofitMember us-gaap:CustomerRelationshipsMember 2018-04-01 2018-04-30 0001639225 lvgo:MyStrengthMember us-gaap:DevelopedTechnologyRightsMember 2019-02-01 2019-02-28 0001639225 lvgo:MyStrengthMember us-gaap:CustomerRelationshipsMember 2019-02-01 2019-02-28 0001639225 lvgo:MyStrengthMember us-gaap:TradeNamesMember 2019-02-01 2019-02-28 0001639225 lvgo:MyStrengthMember 2018-01-01 2018-06-30 0001639225 us-gaap:TradeNamesMember 2018-12-31 0001639225 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0001639225 srt:WeightedAverageMember us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-06-30 0001639225 srt:WeightedAverageMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-06-30 0001639225 us-gaap:CustomerRelationshipsMember 2018-12-31 0001639225 srt:WeightedAverageMember us-gaap:TradeNamesMember 2018-01-01 2018-06-30 0001639225 us-gaap:FurnitureAndFixturesMember 2019-06-30 0001639225 lvgo:ComputerEquipmentAndSoftwareMember 2019-06-30 0001639225 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001639225 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-06-30 0001639225 lvgo:ComputerEquipmentAndSoftwareMember 2018-12-31 0001639225 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001639225 us-gaap:LeaseholdImprovementsMember 2019-06-30 0001639225 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-12-31 0001639225 us-gaap:CustomerRelationshipsMember 2019-06-30 0001639225 srt:WeightedAverageMember us-gaap:TradeNamesMember 2019-01-01 2019-06-30 0001639225 us-gaap:DevelopedTechnologyRightsMember 2019-06-30 0001639225 srt:WeightedAverageMember us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-06-30 0001639225 srt:WeightedAverageMember us-gaap:CustomerRelationshipsMember 2019-01-01 2019-06-30 0001639225 us-gaap:TradeNamesMember 2019-06-30 0001639225 us-gaap:TradeNamesMember 2018-01-01 2018-06-30 0001639225 us-gaap:TradeNamesMember 2019-01-01 2019-06-30 0001639225 us-gaap:TradeNamesMember 2018-04-01 2018-06-30 0001639225 us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-06-30 0001639225 us-gaap:DevelopedTechnologyRightsMember 2018-04-01 2018-06-30 0001639225 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-06-30 0001639225 us-gaap:CustomerRelationshipsMember 2019-04-01 2019-06-30 0001639225 us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-06-30 0001639225 us-gaap:CustomerRelationshipsMember 2018-01-01 2018-06-30 0001639225 us-gaap:TradeNamesMember 2019-04-01 2019-06-30 0001639225 us-gaap:CustomerRelationshipsMember 2018-04-01 2018-06-30 0001639225 us-gaap:DevelopedTechnologyRightsMember 2019-04-01 2019-06-30 0001639225 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001639225 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001639225 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001639225 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001639225 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001639225 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001639225 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001639225 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001639225 lvgo:MountainViewOfficeMember 2019-06-30 0001639225 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001639225 us-gaap:RestrictedStockUnitsRSUMember 2019-06-30 0001639225 us-gaap:RedeemableConvertiblePreferredStockMember 2018-12-31 0001639225 us-gaap:RedeemableConvertiblePreferredStockMember 2019-06-30 0001639225 us-gaap:WarrantMember 2018-12-31 0001639225 us-gaap:EmployeeStockOptionMember 2019-06-30 0001639225 us-gaap:RestrictedStockMember 2019-06-30 0001639225 us-gaap:EmployeeStockOptionMember 2018-12-31 0001639225 us-gaap:WarrantMember 2019-06-30 0001639225 us-gaap:RestrictedStockMember 2018-12-31 0001639225 us-gaap:SubsequentEventMember 2019-07-01 2019-07-31 0001639225 lvgo:WarrantExpiringFebruary2025Member 2019-06-30 0001639225 lvgo:WarrantExpiringApril2025Member 2019-06-30 0001639225 lvgo:WarrantExpiringSeptember2024Member 2019-06-30 0001639225 lvgo:WarrantExpiringSeptember2024Member 2018-12-31 0001639225 lvgo:WarrantExpiringApril2025Member 2018-12-31 0001639225 lvgo:WarrantExpiringFebruary2025Member 2018-12-31 0001639225 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001639225 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001639225 us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0001639225 us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0001639225 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001639225 us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0001639225 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-06-30 0001639225 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0001639225 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-06-30 0001639225 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-06-30 0001639225 us-gaap:SellingAndMarketingExpenseMember 2019-04-01 2019-06-30 0001639225 us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0001639225 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001639225 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0001639225 us-gaap:SellingAndMarketingExpenseMember 2018-04-01 2018-06-30 0001639225 us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-06-30 0001639225 us-gaap:RestrictedStockMember 2019-01-01 2019-06-30 0001639225 lvgo:ServiceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-01 2019-06-30 0001639225 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001639225 lvgo:ServiceAndMarketBasedOptionsAndRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-01 2019-06-30 0001639225 lvgo:ServiceAndMarketBasedOptionsAndRestrictedStockUnitsMember 2019-01-01 2019-06-30 0001639225 us-gaap:RestrictedStockMember 2019-03-01 2019-03-31 0001639225 us-gaap:RestrictedStockMember 2019-06-01 2019-06-30 0001639225 lvgo:ServiceAndMarketBasedRestrictedStockUnitsMember 2019-01-01 2019-01-31 0001639225 lvgo:ServiceBasedRestrictedStockUnitsMember 2019-01-01 2019-01-31 0001639225 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001639225 us-gaap:RestrictedStockMember 2019-01-01 2019-01-31 0001639225 lvgo:ServiceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-06-30 0001639225 lvgo:RestrictedStockUnitsRSUsAndPerformanceSharesMember 2019-04-01 2019-06-30 0001639225 lvgo:ServiceAndMarketBasedOptionsAndRestrictedStockUnitsMember 2019-06-30 0001639225 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-01 2019-06-30 0001639225 us-gaap:RestrictedStockMember 2018-04-01 2018-06-30 0001639225 lvgo:RestrictedStockUnitsRSUsAndPerformanceSharesMember 2019-01-01 2019-06-30 0001639225 lvgo:ServiceAndMarketBasedOptionsAndRestrictedStockUnitsMember 2018-01-01 2018-06-30 0001639225 us-gaap:RestrictedStockMember 2019-04-01 2019-06-30 0001639225 lvgo:PerformanceBasedRestrictedStockUnitsMember 2019-01-01 2019-06-30 0001639225 lvgo:SharebasedPaymentArrangementOptionServiceAndMarketBasedMember 2018-01-01 2018-06-30 0001639225 lvgo:ServiceBasedRestrictedStockUnitsMember 2019-04-01 2019-06-30 0001639225 lvgo:SharebasedPaymentArrangementOptionServiceAndMarketBasedMember 2019-03-01 2019-03-31 0001639225 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0001639225 lvgo:ServiceAndMarketBasedOptionsAndRestrictedStockUnitsMember 2018-04-01 2018-06-30 0001639225 us-gaap:RestrictedStockMember 2018-09-01 2018-09-30 0001639225 lvgo:PerformanceBasedRestrictedStockUnitsMember 2018-01-01 2018-12-31 0001639225 lvgo:ServiceAndMarketBasedOptionsAndRestrictedStockUnitsMember 2019-04-01 2019-06-30 0001639225 lvgo:RestrictedStockUnitsRSUsAndPerformanceSharesMember 2019-06-30 0001639225 lvgo:RestrictedStockUnitsRSUsAndPerformanceSharesMember 2018-12-31 0001639225 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0001639225 us-gaap:PerformanceSharesMember 2019-01-01 2019-06-30 0001639225 2018-01-01 2018-12-31 0001639225 lvgo:PerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-01 2019-06-30 0001639225 lvgo:ServiceBasedRestrictedStockUnitsMember 2019-01-01 2019-06-30 0001639225 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001639225 us-gaap:WarrantMember 2019-04-01 2019-06-30 0001639225 us-gaap:RestrictedStockMember 2018-04-01 2018-06-30 0001639225 us-gaap:RedeemableConvertiblePreferredStockMember 2019-04-01 2019-06-30 0001639225 us-gaap:WarrantMember 2019-01-01 2019-06-30 0001639225 us-gaap:RestrictedStockUnitsRSUMember 2018-04-01 2018-06-30 0001639225 us-gaap:RedeemableConvertiblePreferredStockMember 2019-01-01 2019-06-30 0001639225 us-gaap:WarrantMember 2018-01-01 2018-06-30 0001639225 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0001639225 us-gaap:WarrantMember 2018-04-01 2018-06-30 0001639225 us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0001639225 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0001639225 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0001639225 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0001639225 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0001639225 us-gaap:RedeemableConvertiblePreferredStockMember 2018-01-01 2018-06-30 0001639225 us-gaap:RestrictedStockMember 2019-01-01 2019-06-30 0001639225 us-gaap:RestrictedStockMember 2019-04-01 2019-06-30 0001639225 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001639225 us-gaap:RedeemableConvertiblePreferredStockMember 2018-04-01 2018-06-30 0001639225 lvgo:SubleaseAgreementMember lvgo:ShareholderMember 2014-12-31 0001639225 lvgo:SalaryUnderEmploymentAgreementMember 2019-04-01 2019-06-30 0001639225 lvgo:SharedServiceFeeMember 2019-04-01 2019-06-30 0001639225 lvgo:SalaryUnderEmploymentAgreementMember 2019-01-01 2019-06-30 0001639225 lvgo:SharedServiceFeeMember 2019-01-01 2019-06-30 0001639225 lvgo:A2019EmployeeIncentivePlanMember us-gaap:SubsequentEventMember 2019-07-31 0001639225 lvgo:ChicagoOfficeMember us-gaap:SubsequentEventMember 2019-08-31 0001639225 lvgo:A2019EmployeeIncentivePlanTransferredFrom2014And2008StockIncentivePlansMember us-gaap:SubsequentEventMember 2019-07-31 0001639225 lvgo:A2019EmployeeIncentivePlanMember us-gaap:SubsequentEventMember 2019-07-01 2019-07-31 0001639225 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2019-07-31 0001639225 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:PrimeRateMember 2019-07-01 2019-07-31 0001639225 us-gaap:EmployeeStockMember lvgo:A2019EmployeeStockPurchasePlanMember us-gaap:SubsequentEventMember 2019-07-01 2019-07-31 0001639225 us-gaap:EmployeeStockMember lvgo:A2019EmployeeStockPurchasePlanMember us-gaap:SubsequentEventMember 2019-07-31 0001639225 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2019-07-01 2019-07-31 iso4217:USD iso4217:USD xbrli:shares xbrli:pure xbrli:shares utreg:sqft lvgo:segment lvgo:award_modification
Table of Contents
Index to Financial Statements

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________
FORM 10-Q
_________________________________________
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2019
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-38983
___________________________________________
Livongo Health, Inc.
(Exact name of Registrant as specified in its charter)
___________________________________________
Delaware
 
26-3542036
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification Number)
150 West Evelyn Avenue, Suite 150
Mountain View, California 94041
(866) 435-5643
(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
___________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
        Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
LVGO
The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer 
 
Accelerated filer 
 
 
 
Non-accelerated filer
 
Smaller reporting company 
 
 
 
Emerging growth company 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  
As of August 31, 2019, the registrant had approximately 94,445,000 shares of common stock, $0.001 par value per share, outstanding.
 


Table of Contents
Index to Financial Statements

TABLE OF CONTENTS

 
 
PAGE
 
 
 
 
 
 
 
 
 
 



1

Table of Contents
Index to Financial Statements

NOTE REGARDING FORWARD-LOOKING STATEMENTS
 
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements involve substantial risk and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:
our ability to retain clients and sell additional solutions to new and existing clients;
our ability to attract and enroll new members;
the growth and success of our partners and reseller relationships;
our ability to estimate the size of our target market;
uncertainty in the healthcare regulatory environment;
our future financial performance, including trends in revenue, costs of revenue, gross profit or gross margin, operating expenses, paying users, and free cash flow;
our ability to achieve or maintain profitability;
the demand for our solutions or for chronic condition management in general;
our ability to compete successfully in competitive markets;
our ability to respond to rapid technological changes;
our expectations and management of future growth;
our ability to develop new solutions, or enhancements to our existing solutions, and bring them to market in a timely manner;
our ability to offer high-quality coaching and monitoring;
our ability to attract and retain key personnel and highly qualified personnel;
our ability to protect our brand;
our ability to expand payor relationships;
our ability to maintain, protect, and enhance our intellectual property;
restrictions and penalties as a result of privacy and data protection laws;
our ability to successfully identify, acquire, and integrate companies and assets;
the increased expenses associated with being a public company;
our anticipated uses of net proceeds from our initial public offering; and
the future trading prices of our common stock.

You should not rely upon forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Quarterly Report on Form 10-Q primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations and prospects. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.

The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may make.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our

2

Table of Contents
Index to Financial Statements

statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

 



3

Table of Contents
Index to Financial Statements

PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS.
LIVONGO HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)
(unaudited)
 
June 30, 2019
 
December 31, 2018
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
38,165

 
$
108,928

Accounts receivable, net of allowance for doubtful accounts of $1,054 and $575 as of June 30, 2019, and December 31, 2018, respectively
35,086

 
16,623

Inventories
13,835

 
8,934

Deferred costs, current
10,969

 
6,022

Prepaid expenses and other current assets
5,718

 
4,935

Total current assets
103,773

 
145,442

Property and equipment, net
7,564

 
5,837

Restricted cash, noncurrent
858

 
179

Goodwill
35,794

 
15,709

Intangible assets, net
17,861

 
5,154

Deferred costs, noncurrent
4,947

 
2,447

Other noncurrent assets
6,412

 
5,485

TOTAL ASSETS
$
177,209

 
$
180,253

LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ DEFICIT
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
8,975

 
$
6,377

Accrued expenses and other current liabilities
24,318

 
16,152

Deferred revenue, current
3,467

 
1,614

Advance payments from partner, current
1,343

 
293

Total current liabilities
38,103

 
24,436

Deferred revenue, noncurrent
637

 
437

Advance payment from partner, noncurrent
7,754

 
6,432

Other noncurrent liabilities
3,173

 
3,825

TOTAL LIABILITIES
49,667

 
35,130

Commitments and contingencies (Note 6)

 

Redeemable convertible preferred stock, par value of $0.001 per share; 60,000 and 58,615 shares authorized as of June 30, 2019 and December 31, 2018, respectively; 58,615 and 58,615 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively; aggregate liquidation preference of $237,650 and $237,650, as of June 30, 2019 and December 31, 2018, respectively
237,012

 
236,929

Stockholders’ deficit:
 
 
 
Common stock, par value of $0.001 per share; 100,000 and 99,250 shares authorized as of June 30, 2019 and December 31, 2018, respectively; 20,890 and 17,691 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively
21

 
18

Additional paid-in capital
33,326

 
21,789

Accumulated deficit
(142,817
)
 
(113,613
)
TOTAL STOCKHOLDERS’ DEFICIT
(109,470
)
 
(91,806
)
TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ DEFICIT
$
177,209

 
$
180,253

The accompanying notes are an integral part of these consolidated financial statements.

4

Table of Contents
Index to Financial Statements

LIVONGO HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Revenue
$
40,886

 
$
15,981

 
$
72,947

 
$
28,443

Cost of revenue
12,883

 
4,709

 
23,023

 
7,813

Gross profit
28,003

 
11,272

 
49,924

 
20,630

Operating expenses:
 
 
 
 
 
 
 
Research and development
10,291

 
5,533

 
19,285

 
9,681

Sales and marketing
18,152

 
7,755

 
33,101

 
13,366

General and administrative
13,702

 
4,497

 
27,816

 
8,440

Change in fair value of contingent consideration
282

 

 
956

 

Total operating expenses
42,427

 
17,785

 
81,158

 
31,487

Loss from operations
(14,424
)
 
(6,513
)
 
(31,234
)
 
(10,857
)
Other income, net
185

 
329

 
647

 
465

Loss before provision for income taxes
(14,239
)
 
(6,184
)
 
(30,587
)
 
(10,392
)
Provision for (benefit from) income taxes
5

 
7

 
(1,383
)
 
14

Net loss
$
(14,244
)
 
$
(6,191
)
 
$
(29,204
)
 
$
(10,406
)
Accretion of redeemable convertible preferred stock
(42
)
 
(40
)
 
(83
)
 
(77
)
Net loss attributable to common stockholders
$
(14,286
)
 
$
(6,231
)
 
$
(29,287
)
 
$
(10,483
)
Net loss per share attributable to common stockholders, basic and diluted
$
(0.76
)
 
$
(0.38
)
 
$
(1.58
)
 
$
(0.65
)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted
18,916

 
16,238

 
18,564

 
16,222

The accompanying notes are an integral part of these consolidated financial statements.

5

Table of Contents
Index to Financial Statements

LIVONGO HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
(in thousands)
(unaudited)
 
Redeemable
Convertible Preferred
Stock
 
 
Common Stock
 
Additional
Paid-in
Capital
 
Accumulated
Deficit
 
Total
Stockholders’
Deficit
 
Shares
 
Amount
 
 
Shares
 
Amount
 
Balance as of March 31, 2019
58,615

 
$
236,970

 
 
19,618

 
$
20

 
$
27,586

 
$
(128,573
)
 
$
(100,967
)
Accretion of redeemable convertible preferred stock

 
42

 
 

 

 
(42
)
 

 
(42
)
Issuance of common stock upon exercise of stock options

 

 
 
1,272

 
1

 
1,128

 

 
1,129

Stock-based compensation expense

 

 
 

 

 
4,654

 

 
4,654

Net loss

 

 
 

 

 

 
(14,244
)
 
(14,244
)
Balance as of June 30, 2019
58,615

 
$
237,012

 
 
20,890

 
$
21

 
$
33,326

 
$
(142,817
)
 
$
(109,470
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance as of March 31, 2018
45,960


$
132,054

 
 
17,338


$
17


$
14,724


$
(84,446
)

$
(69,705
)
Issuance of Series E redeemable convertible preferred stock, net of issuance costs of $250
12,655

 
104,750

 
 

 

 

 

 

Accretion of redeemable convertible preferred stock


 
40

 
 

 

 
(40
)
 

 
(40
)
Issuance of common stock upon exercise of stock options, net

 

 
 
73

 

 
71

 

 
71

Stock-based compensation expense

 

 
 

 

 
967

 

 
967

Net loss

 

 
 

 

 

 
(6,191
)
 
(6,191
)
Balance as of June 30, 2018
58,615

 
$
236,844

 
 
17,411

 
$
17

 
$
15,722

 
$
(90,637
)
 
$
(74,898
)
The accompanying notes are an integral part of these consolidated financial statements.

6

Table of Contents
Index to Financial Statements

LIVONGO HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
(in thousands)
(unaudited)
 
Redeemable
Convertible
Preferred
Stock
 
 
Common Stock
 
Additional
Paid-in
Capital
 
Accumulated
Deficit
 
Total
Stockholders’
Deficit
 
Shares
 
Amount
 
 
Shares
 
Amount
 
Balance as of December 31, 2018
58,615

 
$
236,929

 
 
17,691

 
$
18

 
$
21,789

 
$
(113,613
)
 
$
(91,806
)
Accretion of redeemable convertible preferred stock

 
83

 
 

 

 
(83
)
 

 
(83
)
Issuance of common stock upon exercise of stock options, net

 

 
 
1,726

 
2

 
1,441

 

 
1,443

Issuance of restricted stock awards

 

 
 
982

 
1

 
(1
)
 

 

Issuance of common stock upon vesting of restricted stock units

 

 
 
491

 

 

 

 

Stock-based compensation expense

 

 
 

 

 
10,180

 

 
10,180

Net loss

 

 
 

 

 

 
(29,204
)
 
(29,204
)
Balance as of June 30, 2019
58,615

 
$
237,012

 
 
20,890

 
$
21

 
$
33,326

 
$
(142,817
)
 
$
(109,470
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance as of December 31, 2017
45,960


$
132,017



17,030


$
17


$
13,806


$
(80,231
)

$
(66,408
)
Issuance of Series E redeemable convertible preferred stock, net of issuance costs of $250
12,655


104,750












Accretion of redeemable convertible preferred stock


77







(77
)



(77
)
Issuance of common stock upon exercise of stock options





381




275




275

Stock-based compensation expense









1,718




1,718

Net loss











(10,406
)

(10,406
)
Balance as of June 30, 2018
58,615


$
236,844



17,411


$
17


$
15,722


$
(90,637
)

$
(74,898
)
The accompanying notes are an integral part of these consolidated financial statements.

7

Table of Contents
Index to Financial Statements

LIVONGO HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
 
Six Months Ended June 30,
 
2019
 
2018
CASH FLOWS FROM OPERATING ACTIVITIES
 
 
 
Net loss
$
(29,204
)
 
$
(10,406
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation and amortization expense
1,450

 
472

Amortization of intangible assets
1,193

 
172

Change in fair value of contingent consideration
956

 

Allowance for doubtful accounts
511

 
38

Stock-based compensation expense
10,147

 
1,691

Deferred income taxes
(1,396
)
 

Changes in operating assets and liabilities, net of impact of acquisitions:
 
 
 
Accounts receivable, net
(17,637
)
 
(3,571
)
Inventories
(4,901
)
 
522

Deferred costs
(7,447
)
 
(2,109
)
Prepaid expenses and other assets
327

 
(62
)
Accounts payable
2,257

 
(123
)
Accrued expenses and other liabilities
758

 
497

Deferred revenue
653

 
89

Advance payments from partner
2,372

 
(132
)
Net cash used in operating activities
(39,961
)
 
(12,922
)
CASH FLOWS FROM INVESTING ACTIVITIES
 
 
 
Purchases of property and equipment
(628
)
 
(366
)
Capitalized internal-use software costs
(2,378
)
 
(1,339
)
Acquisitions, net of cash acquired
(27,435
)
 
(12,268
)
Escrow deposit
434

 
(7,000
)
Net cash used in investing activities
(30,007
)
 
(20,973
)
CASH FLOWS FROM FINANCING ACTIVITIES
 
 
 
Deferred acquisition related payment

 
(1,000
)
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

 
104,810

Proceeds from exercise of stock options, net of repurchases
1,443

 
275

Payment of deferred offering costs
(1,559
)
 

Net cash provided by (used in) financing activities
(116
)
 
104,085

Net increase (decrease) in cash, cash equivalents, and restricted cash
(70,084
)
 
70,190

Cash, cash equivalents, and restricted cash, beginning of period
109,107

 
61,523

Cash, cash equivalents, and restricted cash, end of period
$
39,023

 
$
131,713

Reconciliation of cash, cash equivalents, and restricted cash:
 
 
 
Cash and cash equivalents
$
38,165

 
$
131,433

Restricted cash
858

 
280

Total cash, cash equivalents, and restricted cash, end of period
$
39,023

 
$
131,713

SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:
 
 
 
Accretion of redeemable convertible preferred stock
$
83

 
$
77

Purchases of property and equipment included in accounts payable and accrued liabilities
$
87

 
$
(23
)
Contingent consideration liability related to Retrofit acquisition
$
1,316

 
$
6,204

Contingent consideration liability related to myStrength acquisition
$
3,300

 
$

Unpaid working capital adjustment related to myStrength acquisition
$
119

 
$

Capitalized internal-use software costs in accounts payable and accrued liabilities
$
(61
)
 
$
(4
)
Unpaid deferred offering costs
$
1,312

 
$

Unpaid offering costs related to issuance of Series E redeemable convertible preferred stock
$

 
$
60

The accompanying notes are an integral part of these consolidated financial statements.

8

Table of Contents
Index to Financial Statements

LIVONGO HEALTH, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1. Organization and Description of Business
Description of Business
Livongo Health, Inc. (“we”, “us”, “the Company”, or “Livongo”) was incorporated in the state of Delaware on October 16, 2008, under the name of EosHealth, Inc. In September 2014, we changed our name to Livongo Health, Inc. Livongo empowers people with chronic conditions to live better and healthier lives. We have created a unified platform that provides smart, cellular-connected devices, supplies, informed coaching, data science-enabled insights and facilitates access to medications across multiple chronic conditions to help our members lead better lives. We currently offer Livongo for Diabetes, Livongo for Hypertension, Livongo for Prediabetes and Weight Management, and Livongo for Behavioral Health by myStrength. We create consumer-first experiences with high member satisfaction, measurable, sustainable health outcomes, and more cost-effective care for our members and our clients. This approach is leading to better clinical and financial outcomes while also creating a better experience for people with chronic conditions and their care team of family, friends, and medical professionals. Our headquarters is located in Mountain View, California, and we serve customers throughout North America.
Initial Public Offering
In July 2019, we completed our initial public offering ("IPO") in which we issued and sold 14,590,050 shares of our common stock at an offering price of $28.00 per share, including 1,903,050 shares of common stock pursuant to the exercise in full of the underwriters' option to purchase additional shares. We received net proceeds of $377.7 million, after deducting underwriting discounts and commissions of $28.6 million and estimated deferred offering costs of $2.2 million. Deferred offering costs are capitalized and consist of fees and expenses incurred in connection with the sale of our common stock in an IPO, including the legal, accounting, printing and other IPO-related costs. Upon completion of the IPO, these deferred offering costs were reclassified to stockholders’ equity and recorded against the proceeds from the offering. Immediately prior to the closing of the IPO, all 58,615,488 shares of our then-outstanding redeemable convertible preferred stock automatically converted into 58,615,488 shares of common stock at their respective conversion ratios and we reclassified $236.9 million of redeemable convertible preferred stock to additional paid-in capital and $0.1 million to common stock on our condensed consolidated balance sheet.
Reverse Stock Split
In June 2019, our board of directors and stockholders approved a 1-for-2 reverse stock split of our common stock and redeemable convertible preferred stock, which was effected on June 27, 2019 pursuant to an amendment to our amended and restated certificate of incorporation. The par value of the common stock and redeemable convertible preferred stock was not adjusted as a result of the reverse stock split. All references to redeemable convertible preferred stock, common stock, options to purchase common stock, restricted stock awards, restricted stock units, common stock warrants, per share data, and related information included in this Quarterly Report on Form 10-Q have been adjusted to reflect this reverse stock split for all periods presented.

2. Summary of Significant Accounting Policies
Basis of Presentation
The condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of Livongo Health, Inc. and our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated.
The accompanying interim condensed consolidated balance sheets as of June 30, 2019, the interim condensed consolidated statements of operations and the interim condensed consolidated statements of redeemable convertible preferred stock and stockholders’ deficit for the three and six months ended June 30, 2019 and 2018, and the interim condensed consolidated statements of cash flows for the six months ended June 30, 2019 and 2018 are unaudited. These interim condensed consolidated financial statements have been prepared on a basis consistent with the annual consolidated financial statements and, in the opinion of

9

Table of Contents
Index to Financial Statements

management, include all adjustments necessary to fairly state our financial position as of June 30, 2019, the results of our operations for the three and six months ended June 30, 2019 and 2018 and result of our cash flows for the six months ended June 30, 2019 and 2018. The financial data and other financial information disclosure in the notes to these interim condensed consolidated financial statements related to the three and six months periods are also unaudited. The results for the three and six months ended June 30, 2019 are not necessarily indicative of the operating results expected for the year ending December 31, 2019 or any future period.
Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in the final prospectus for our IPO filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended (File No. 333-232412) on July 25, 2019.
Comprehensive Loss
For the three and six months ended June 30, 2019 and 2018, there was no difference between comprehensive loss and net loss.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the financial statements, as well as the reported amounts of revenue and expenses during the periods presented. Such estimates, judgments, and assumptions include: revenue recognition, assessment of the useful life and recoverability of long-lived assets, fair values of stock-based awards, contingent consideration in business combinations, and income taxes. To the extent there are material differences between these estimates, judgments, or assumptions and actual results, our financial statements will be affected.
Emerging Growth Company Status
We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period and, as a result, we will not adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies until required by private company accounting standards.
Concentration of Risk
Financial instruments that potentially subject us to credit risk consist principally of cash, cash equivalents, and accounts receivable. We maintain our cash primarily with domestic financial institutions of high credit quality, which may exceed federal deposit insurance corporation limits. We invest our cash equivalents in highly rated money market funds. We have not experienced any losses in such accounts. We believe we are not exposed to any significant credit risk on cash and cash equivalents and perform periodic evaluations of the credit standing of such institutions.
Our sales are predominately to self-insured employers, healthcare providers, and insurance carriers located throughout North America. Accounts receivable are recorded at the invoiced amount, and are stated at realizable value, net of an allowance for doubtful accounts. We perform ongoing assessments and credit evaluations of our clients to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with clients. We have not experienced significant credit losses from our accounts receivable.

10

Table of Contents
Index to Financial Statements

Significant customers and partners are those which represent 10% or more of our net accounts receivable balance or revenue during the period at each respective consolidated balance sheet date. There were no customers that represented 10% or more of our accounts receivable balance or revenue for the periods presented. For each significant partner that represented 10% or more of our accounts receivable balance or revenue during the periods presented, revenue as a percentage of total revenue and accounts receivable as a percentage of net accounts receivable were as follows:
 
Revenue
 
Accounts Receivable
 
 Three Months Ended June 30,
 
Six Months Ended June 30,
 
June 30,
 
December 31,
 
2019
 
2018
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
(unaudited)
 
 
 
 
Partner A
27
%
 
33
%
 
26
%
 
34
%
 
10
%
 
28
%
Partner B
24
%
 
*

 
24
%
 
*

 
27
%
 
13
%
_________________
*
Less than 10% of total revenue or net accounts receivable
We utilize a limited number of manufacturing vendors to build and assemble our products. The hardware components included in our devices are sourced from various suppliers by the manufacturer and are principally industry standard parts and components that are available from multiple vendors. Quality or performance failures of the glucometer or changes in the contractors’ or vendors’ financial or business condition could disrupt our ability to supply quality products to our customers and thereby have a material adverse impact on our business, financial condition and results of operations.
Recent Accounting Pronouncements Adopted
Comprehensive Income: In February 2018, the FASB issued ASU No. 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which provides financial statement preparers with an option to reclassify stranded tax effects within accumulated other comprehensive income to retained earnings in each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act (or portion thereof) is recorded. This ASU becomes effective for us for the year ending December 31, 2019 and the interim periods therein. Early adoption is permitted. The amendments in this ASU should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act is recognized. The adoption of this ASU did not have a material impact on our condensed consolidated financial statements.
New Accounting Pronouncements Not Yet Adopted
Leases: In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases, and ASU No. 2018-11, Leases (Topic 842), Targeted Improvements, which affect certain aspects of the previously issued guidance. In December 2018, the FASB issued ASU No. 2018-20, Narrow-Scope Improvements for Lessor, Leases (Topic 842), which provides guidance on sales tax and other taxes collected from lessees. In June 2019, the FASB issued ASU No. 2019-01, Codification Improvements to Topic 842, Leases, which affect certain aspects of the previously issued guidance. Amendments include an additional transition method that allows entities to apply the new standard on the adoption date and recognize a cumulative effect adjustment to the opening balance of retained earnings, as well as a new practical expedient for lessors. This ASU is effective for us for the year ending December 31, 2020 and interim periods within the year ending December 31, 2021. Early adoption is permitted. We are currently evaluating adoption methods and whether this ASU will have a material impact on our condensed consolidated financial statements.
Stock-Based Compensation: In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting. The standard simplifies the accounting for share-based payments granted to nonemployees for goods and services and aligns most of the guidance on such payments to the nonemployees with the requirements for share-based payments granted to employees. ASU No. 2018-07 is effective for us for the year ending December 15, 2020, and interim periods within the year ending December 31, 2021. Early adoption is permitted. We are currently evaluating the impact of this ASU on our condensed consolidated financial statements.

11

Table of Contents
Index to Financial Statements

Internal Use Software: In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use-software. This ASU is effective for us for the year ending December 31, 2021, and interim periods within the year ending December 31, 2022. Early adoption is permitted. We are currently evaluating the impact of this ASU on our condensed consolidated financial statements.
Revenue Recognition: In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASC 606”), which amends the existing accounting standards for revenue recognition. ASU No. 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. ASU No. 2014-09 will be effective for us for our annual results for the year ending December 31, 2019, and our interim periods beginning after December 31, 2019. Subsequently, the FASB has issued the following standards related to ASU No. 2014-09: ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations; ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing; ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients; and ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, which clarifies narrow aspects of ASC 606 or corrects unintended application of the guidance.
We plan to adopt the new revenue standard using the modified retrospective transition method when it becomes effective for us, which is the year ending December 31, 2019 and interim periods beginning after December 31, 2019. We are in the process of reviewing our significant contracts and are evaluating the impact of the new standard. Based on our preliminary impact assessment of the Livongo for Diabetes solution, we believe that the overall promise to our customers is to improve member health results and reduce healthcare costs, and the delivery of this promise would not be possible without the integration of Livongo devices, supplies, access to our web-based platform, and clinical and data services. The promises to transfer the goods and services are not separately identifiable in accordance with ASC 606-10-25-19b, evidenced by the fact that we provide a significant service of integrating the goods and services provided by us (i.e., inputs) into a combined output (i.e., member behavior modifications) that result in the fulfillment of our promise to our customers. We are currently finalizing our assessment of the full accounting impact of the standard; however, we have identified the treatment of variable consideration will be impacted upon our adoption. Additionally, incremental costs of obtaining a contract will be recognized as assets to the extent the period of benefit is greater than one year. We continue to evaluate the effect that the standard will have on our condensed consolidated financial statements, including disclosures, and preliminary assessments are subject to change.
3. Business Combinations
Retrofit Inc.
In April 2018, we acquired all of the issued and outstanding shares of Retrofit Inc. (“Retrofit”), a privately-held, Illinois-based entity, and a leading provider of weight-management and disease-prevention programs, through a share purchase agreement (the “Retrofit Purchase Agreement”) in exchange for cash consideration (the “Retrofit Acquisition”). The Retrofit Acquisition provides us with an evidence-based diabetes prevention program that enhances our data science capabilities and our expertise in holistic weight management including nutrition, exercise and mindset.
The total consideration transferred as part of the Retrofit Acquisition consisted of a cash payment on the closing date, adjusted for customary closing adjustments, of $12.4 million. Upon the close of the Retrofit Acquisition, as part of the Retrofit Purchase Agreement, we placed in escrow an earn-out consideration of $7.0 million held by a third-party escrow agent to be released to the former stockholders of Retrofit contingent upon achieving future qualified member targets as determined on December 31, 2018, 2019, and 2020 (the “Retrofit Contingent Consideration”). We recorded a corresponding escrow asset of $7.0 million on our consolidated balance sheet. We estimated the fair value of the Retrofit Contingent Consideration to be $6.2 million as of the acquisition date using a Monte Carlo simulation model, which together with the cash consideration resulted in total purchase consideration of $18.6 million. The Retrofit Contingent Consideration is subject to remeasurement at each reporting date until the payments are released from escrow, with the remeasurement adjustment reported in our consolidated statements of operations. On December 31, 2018, we subsequently reduced the fair value of the Retrofit Contingent Consideration to $5.0 million, with the change in fair value of $1.2 million recorded in our condensed consolidated statements of operations. During each of the three and six months ended June 30, 2019, the fair value of the Retrofit Contingent Consideration was reduced and we recorded a benefit of $0.3 million within the change in fair value of contingent consideration on our condensed consolidated statement of operations.

12

Table of Contents
Index to Financial Statements

In April 2019, we released $1.8 million from the escrow deposit, of which $1.3 million was paid to the former stockholders of Retrofit. As of June 30, 2019, the remaining Retrofit Contingent Consideration was $3.4 million.
Additionally, we recognized $0.3 million of acquisition-related costs as general and administrative expense in our condensed consolidated statements of operations during the three and six months ended June 30, 2018.
The purchase consideration of $18.6 million was allocated as follows:
 
Amount
 
(in thousands)
Cash and cash equivalents
$
87

Accounts receivable
409

Inventories
56

Prepaid expenses and other current assets
124

Property and equipment
52

Intangible assets
5,580

Total assets acquired
6,308

Accounts payable
366

Accrued expenses and other liabilities
394

Deferred revenue
212

Total liabilities assumed
972

Goodwill
13,223

Total purchase consideration
$
18,559


The following table sets forth the components of identifiable intangible assets acquired and their estimated useful lives as of the acquisition date:
 
Cost
 
Useful Life
 
(in thousands)
 
(years)
Customer relationships
$
3,890

 
10.0
Developed technology
1,650

 
5.0
Trade name
40

 
2.0
Total
$
5,580

 
 

The fair value assigned to developed technology and trade name was determined using a relief from royalty method, where the owner of the asset realizes a benefit from owning the intangible asset rather than paying a rental or royalty rate for use of the asset. The fair value of customer relationships was determined using the multi-period excess earnings method, which estimates the revenue and cash flows derived from the asset and then deducts portions of the cash flows that can be attributed to supporting assets otherwise recognized.
Goodwill represents the excess of the purchase consideration over the estimated acquisition date fair value of the net tangible and intangible assets acquired and liabilities assumed. Goodwill is primarily attributable to expected post-acquisition synergies from integrating Retrofit’s assembled workforce and developed technology into our product offerings and cross-selling opportunities. Goodwill recorded is not deductible for income tax purposes.
Revenue and net income of Retrofit of $0.7 million and $0.5 million for the three months ended June 30, 2019, respectively, and $2.1 million and $1.6 million for the six months ended June 30, 2019, respectively, were included in our condensed consolidated statement of operations. Revenue and net loss of Retrofit of $1.1 million and $0.8 million, respectively, for each of the three and six months ended June 30, 2018, respectively, were included in our condensed consolidated statement of operations.

13

Table of Contents
Index to Financial Statements

Unaudited Pro Forma Financial Information
The following unaudited pro forma information presents the combined results of operations as if the Retrofit Acquisition had been completed on January 1, 2017, the beginning of the comparable prior annual reporting period. The unaudited pro forma results include adjustments primarily related to the following: (i) interest expense related to the legacy debt of Retrofit that was not acquired; (ii) amortization of the acquired intangible assets; (iii) recognition of post-acquisition stock-based compensation expense; (iv) the inclusion of acquisition-related costs as of the earliest period presented; and (v) the associated tax impact of the acquisitions and these unaudited pro forma adjustments.
 
Six Months Ended
 
June 30, 2018
 
(in thousands)
Revenue
$
29,951

Net loss
$
(11,941
)

myStrength, Inc.
In February 2019 we acquired all of the issued and outstanding shares of myStrength, Inc. (“myStrength”), a privately-held entity based in Denver, Colorado, and a leading provider of digital behavioral health solutions through an agreement and plan of merger (the “myStrength Purchase Agreement”) in exchange for cash consideration (the “myStrength Acquisition”). The myStrength Acquisition will enable us to more fully address the health of the whole person by bringing behavioral health conditions including depression, anxiety, stress, substance use disorder, chronic pain, opioid addiction and recovery, and insomnia to our Applied Health Signals solution.
The total consideration for the myStrength Acquisition was $30.1 million in cash, subject to a closing adjustment of $0.1 million. As part of the myStrength Purchase Agreement, we are obligated to pay an earn-out consideration up to $5.0 million contingent upon satisfying future milestones for the year ending December 31, 2019 (the “myStrength Contingent Consideration”). We estimated the fair value of the myStrength Contingent Consideration to be $3.3 million as of the acquisition date using a Monte Carlo simulation model, which together with the cash consideration, resulted in total purchase consideration of $33.5 million. The myStrength Contingent Consideration is subject to remeasurement at each reporting date until the payments are made, with the remeasurement adjustment reported in our consolidated statements of operations. On June 30, 2019, we subsequently increased the fair value of the myStrength Contingent Consideration to $4.5 million and recorded an expense of $0.6 million and $1.2 million for the three and six months ended June 30, 2019, respectively, recorded in our condensed consolidated statements of operations.
The purchase consideration of $33.5 million was allocated as follows:
 
Amount
 
(in thousands)
Cash and cash equivalents
$
2,643

Accounts receivable
1,337

Other current assets
140

Property and equipment
114

Intangible assets
13,900

Other assets
34

Total assets acquired
18,168

Accounts payable
173

Accrued expenses and other liabilities
1,787

Deferred revenue
1,400

Deferred tax liability, net
1,396

Total liabilities assumed
4,756

Goodwill
20,085

Total purchase consideration
$
33,497



14

Table of Contents
Index to Financial Statements

The following table sets forth the components of identifiable intangible assets acquired and their estimated useful lives as of the acquisition date:
 
Cost
 
Useful Life
 
(in thousands)
 
(years)
Customer relationships
$
4,300

 
7.0
Developed technology
9,200

 
7.0
Trade name
400

 
5.0
Total
$
13,900

 
 

The estimated fair values of the intangible assets acquired were determined based on the income approach to measure the fair value of the trade name, customer relationships, and developed technology. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy.
Additionally, during the three and six months ended June 30, 2019, we incurred a total of $0.3 million of acquisition-related costs as a result of the myStrength acquisition.
Goodwill represents the excess of the purchase consideration over the estimated acquisition date fair value of the net tangible and intangible assets acquired and liabilities assumed. Goodwill is primarily attributable to expected post-acquisition synergies from integrating myStrength’s assembled workforce and developed technology into our product offerings and cross-selling opportunities. Goodwill recorded is not deductible for income tax purposes.
Revenue and net loss of myStrength of $1.8 million and $0.1 million, respectively, for the three months ended June 30, 2019, were included in our condensed consolidated statement of operations. Revenue and net loss of myStrength of $2.8 million and $0.5 million, respectively, for the six months ended June 30, 2019, were included in our condensed consolidated statement of operations.
Unaudited Pro Forma Financial Information
The following unaudited pro forma information presents the combined results of operations as if the myStrength Acquisition had been completed on January 1, 2018, the beginning of the comparable prior annual reporting period. The unaudited pro forma results include adjustments primarily related to the following: (i) interest expense related to the legacy debt of myStrength that was not acquired; (ii) amortization of the acquired intangible assets; (iii) fair value adjustment for deferred revenue; (iv) the inclusion of acquisition-related costs as of the earliest period presented; and (v) the associated tax impact of the acquisitions and these unaudited pro forma adjustments.
 
Six Months Ended June 30,
 
2019
 
2018
 
(in thousands)
Revenue
$
73,544

 
$
30,264

Net loss
$
(27,868
)
 
$
(13,818
)


4. Balance Sheet Components
Inventories
Inventories of $13.8 million and $8.9 million, as of June 30, 2019 and December 31, 2018, respectively, consisted of finished goods.

15

Table of Contents
Index to Financial Statements

Property and Equipment, Net
Property and equipment consisted of the following:
 
June 30,
 
December 31,
 
2019
 
2018
 
(in thousands)
Computer equipment and software
$
1,145

 
$
652

Furniture and fixtures
914

 
730

Capitalized internal-use software
8,003

 
5,653

Leasehold improvements
730

 
585

Property and equipment
10,792

 
7,620

Less: accumulated depreciation
(3,228
)
 
(1,783
)
Property and equipment, net
$
7,564

 
$
5,837


Depreciation and amortization expense was $0.8 million and $0.3 million for the three months ended June 30, 2019 and 2018, respectively, and $1.5 million and $0.5 million for the six months ended June 30, 2019 and 2018, respectively.
Intangible Assets, Net
Intangible assets consisted of the following as of June 30, 2019:
 
Gross Value
 
Accumulated
Amortization
 
Net Book
Value
 
Weighted-
Average
Remaining
Useful Life
 
(in thousands)
 
(years)
Customer relationships
$
8,190

 
$
(726
)
 
$
7,464

 
7.6
Developed technology
11,020

 
(1,009
)
 
10,011

 
6.2
Trade name
448

 
(62
)
 
386

 
4.4
Total
$
19,658

 
$
(1,797
)
 
$
17,861

 
 
Intangible assets consisted of the following as of December 31, 2018:
 
Gross Value
 
Accumulated
Amortization
 
Net Book
Value
 
Weighted-
Average
Remaining
Useful Life
 
(in thousands)
 
(years)
Customer relationships
$
3,890

 
$
(266
)
 
$
3,624

 
9.3
Developed technology
1,820

 
(329
)
 
1,491

 
4.3
Trade names
48

 
(9
)
 
39

 
1.4
Total
$
5,758

 
$
(604
)
 
$
5,154

 
 

Amortization expense for intangible assets for three and six months ended June 30, 2019 and 2018 is as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
 
(in thousands)
Customer relationships
$
251

 
$
81

 
$
418

 
$
81

Developed technology
353

 
77

 
730

 
86

Trade names
25

 
5

 
45

 
5

Total
$
629

 
$
163

 
$
1,193

 
$
172



16

Table of Contents
Index to Financial Statements

The expected future amortization expense related to intangible assets as of June 30, 2019 was as follows:
 
Amount
 
(in thousands)
Remainder of 2019
$
1,392

2020
2,769

2021
2,762

2022
2,750

2023
2,494

Thereafter
5,694

Total
$
17,861


Goodwill
Goodwill consisted of the following:
 
Carrying Amount
 
(in thousands)
Beginning balance as of December 31, 2018
$
15,709

Goodwill acquired (Note 3)
20,085

Ending balance as of June 30, 2019
$
35,794


Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following:
 
June 30,
 
December 31,
 
2019
 
2018
 
(in thousands)
Short-term deposits
$
261

 
$
718

Prepaid rent
175

 
227

Other prepaid expenses
2,331

 
2,084

Escrow deposit, current
2,100

 
1,750

Employee Receivable
741

 

Other current assets
110

 
156

Total
$
5,718

 
$
4,935


Other Noncurrent Assets
Other noncurrent assets consisted of the following:
 
June 30,
 
December 31,
 
2019
 
2018
 
(in thousands)
Escrow deposit, noncurrent
$
3,150

 
$
5,250

Other
3,262

 
235

Total
$
6,412

 
$
5,485



17

Table of Contents
Index to Financial Statements

Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following:
 
June 30,
 
December 31,
 
2019
 
2018
 
(in thousands)
Accrued payroll and employee benefits
$
3,019

 
$
1,447

Accrued bonus
4,435

 
5,857

Accrued sales and use taxes
1,897

 
1,887

Accrued rebates
1,081

 
609

Vendor accruals
3,083

 
1,574

Accrued commissions
1,598

 
1,470

Contingent consideration, current
4,954

 
1,316

Accrued professional services
1,385

 
295

Other accrued expenses
2,866

 
1,697

Total
$
24,318

 
$
16,152


5. Fair Value Measurements
The following table sets forth the fair value of our financial assets and liabilities by level within the fair value hierarchy:
 
June 30, 2019
 
Level 1
 
Level 2
 
Level 3
 
Fair Value
 
(in thousands)
Assets
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
22,391

 
$

 
$

 
$
22,391

Total assets at fair value
$
22,391

 
$

 
$

 
$
22,391

Liabilities
 
 
 
 
 
 
 
Other current liabilities—contingent consideration
$

 
$

 
$
4,954

 
$
4,954

Other noncurrent liabilities—contingent consideration

 

 
2,990

 
2,990

Total liabilities at fair value
$

 
$